Magnitude Biosciences
PrivateLast Round
Seed
May 27, 2025
Total Funding Raised
$2.99M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Magnitude Biosciences operates in Healthcare & Life Sciences and is based in Sedgefield. Its latest recorded funding round was a Seed round in May 2025.
Magnitude Biosciences is a biotechnology company that provides contract research services using a patented in-vivo testing platform with C. elegans and automated imaging technology to accelerate drug discovery and toxicity testing.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Clinical Trials, Biotech Equipment
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts, Hardware + Subscription
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Magnitude Biosciences Comparables
Compare Magnitude Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ora Biomedical, Inc. | 89% | |
| vivoVerse | 86% | |
| Fujian SunyBiotech Co., Ltd. | 84% |
For institutional investors. Book with your work email.
Magnitude Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | May 27, 2025 | ||||
| Grant | Jun 5, 2023 | ||||
| Grant | Nov 15, 2022 | ||||
| Convertible Debt | Aug 21, 2020 | ||||
| Seed | Dec 2, 2019 | ||||
Seed | Jan 17, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Magnitude Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Future Fund | Convertible Debt |
| British Business Bank | Seed |
| Innovate UK | Grant, Seed |
| Saker Capital LLP | Seed, Grant, Convertible Debt |
| Northstar Ventures | Convertible Debt, Grant, Seed |
| Innovate UK | Seed |
| Maven Capital Partners | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 6, 2026
Featured in the North East's businesses to watch list.
- Aug 21, 2026
Monthly visitors grew 42% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- recognized_asNov 6, 2026
Magnitude Biosciences Ltd. is recognised among 20 North East organisations to watch, highlighting its innovative life sciences work and its contribution to the region’s future growth.
- receives_financingSep 16, 2026
On Sep 17th '26, Magnitude Biosciences Ltd. closes a $1.3M funding round to advance its worm-based longevity drug discovery platform.
- invests_into_assetsSep 16, 2026
New funding helps Magnitude Biosciences Ltd. invest in equipment and automation, scale its VivoScan(TM) platform, expand commercial work with pharmaceutical companies and recruit staff.
- receives_financingSep 15, 2026
Magnitude Biosciences Ltd. can access a $291K Innovate UK Investor Partnership grant as part of its Northstar Ventures-led £1.3m funding round, which includes Maven-managed regional funds and new angel investors and supports scaling its VivoScan platform.
- receives_financingSep 15, 2026
Magnitude Biosciences Ltd. has secured $1.74M in funding to accelerate the commercialisation of its VivoScan™ in vivo high-throughput screening platform in United Kingdom on Sep 15th '26.
For institutional investors. Book with your work email.
Magnitude Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Magnitude Biosciences's valuation, stock price, and market status.
Is Magnitude Biosciences a public or private company?
Magnitude Biosciences is a private company.
What is the current stock price of Magnitude Biosciences?
Magnitude Biosciences is a private company, so its shares have no public market price. Caplight tracks Magnitude Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Magnitude Biosciences worth (valuation)?
Valuation information for Magnitude Biosciences is not publicly available.
Can I buy Magnitude Biosciences stock?
Magnitude Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Magnitude Biosciences's last funding round?
Magnitude Biosciences's most recent funding round was Seed on May 27, 2025.
Who are the main investors in Magnitude Biosciences?
Key investors in Magnitude Biosciences include Innovate UK, Northstar Ventures, Maven Capital Partners.
Will Magnitude Biosciences IPO soon?
No public IPO plans have been announced for Magnitude Biosciences.
How can I track Magnitude Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Magnitude Biosciences's shares on secondary markets.